• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents

Article

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with.

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with. “Now, until recently that whole idea of risks versus benefits was really about the benefits of the medicine versus the risks of tolerability issues,” said Dr Kantor. “So not of major safety issues.” Self-injectables may be a burden to some, they have a long-term safety profile. Though convenient, newer oral medications have more safety concerns and risks. It is imperative that physicians work with their individual patients to manage risks when using new agents.

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Giulio Cossu, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.